The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The paper highlights how conditions common across India—including anemia, inherited hemoglobin disorders, and glucose-6-phosphate dehydrogenase (G6PD) deficiency—can significantly distort HbA1c readings
The new OMR facility, located in Chennai’s medical hub, is close to leading hospitals and offers excellent road and air connectivity
The revenues this quarter are in line with the outlook we envisaged for the year
HCG clinicians contributing to one of the largest bodies of oncology research from India
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Subscribe To Our Newsletter & Stay Updated